L&C Bio Co Ltd
KOSDAQ:290650
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
L&C Bio Co Ltd
Note Receivable
L&C Bio Co Ltd
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
L&C Bio Co Ltd
KOSDAQ:290650
|
Note Receivable
₩993m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Note Receivable
₩16.5B
|
CAGR 3-Years
-51%
|
CAGR 5-Years
12%
|
CAGR 10-Years
38%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Note Receivable
₩110m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
L&C Bio Co Ltd
Glance View
L&C BIO Co., Ltd. develops soft tissue, allografts, and medical devices. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-11-01. The firm mainly manufactures and sells human tissue transplant materials used for tissue repair and filler. The firm also produces and sells human tissue-based medical devices and Cosmeceuticals. Its products are used in vascular surgeries, plastic surgeries, general surgeries and others.
See Also
What is L&C Bio Co Ltd's Note Receivable?
Note Receivable
993m
KRW
Based on the financial report for Sep 30, 2025, L&C Bio Co Ltd's Note Receivable amounts to 993m KRW.
What is L&C Bio Co Ltd's Note Receivable growth rate?
Note Receivable CAGR 5Y
-19%
Over the last year, the Note Receivable growth was -30%. The average annual Note Receivable growth rates for L&C Bio Co Ltd have been 5% over the past three years , -19% over the past five years .
